UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 467

Sortiert nach

Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study

Annals of oncology, 2014-07, Vol.25 (7), p.1340-1346

2014

Volltextzugriff (PDF)

A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy

Annals of oncology, 2014-07, Vol.25 (7), p.1333-1339

2014

Volltextzugriff (PDF)

2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients

Annals of oncology, 2016-09, Vol.27 (suppl 5), p.v119-v133

2016

Volltextzugriff (PDF)

Request for regulatory guidance for cancer cachexia intervention trials

Journal of cachexia, sarcopenia and muscle, 2015-12, Vol.6 (4), p.272-274

2015

Volltextzugriff (PDF)

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference

Annals of oncology, 2010-05, Vol.21 (suppl-5), p.v232-v243

2010

Volltextzugriff (PDF)

Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy

Annals of oncology, 2018-07, Vol.29 (7), p.1535-1540

2018

Volltextzugriff (PDF)

Randomized Phase II Study of the Neurokinin 1 Receptor Antagonist CJ-11,974 in the Control of Cisplatin-Induced Emesis

Journal of clinical oncology, 1999-01, Vol.17 (1), p.338-343

1999

Volltextzugriff (PDF)

2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting

ESMO open, 2024-02, Vol.9 (2), p.102195-102195, Article 102195

2024

Volltextzugriff (PDF)

Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy

Journal of clinical oncology, 1998-04, Vol.16 (4), p.1568-1573

1998

Volltextzugriff (PDF)

A randomized trial of the electronic Lung Cancer Symptom Scale for quality-of-life assessment in patients with advanced non-small-cell lung cancer

Current oncology (Toronto), 2020-04, Vol.27 (2), p.e156-162

2020

Volltextzugriff (PDF)

Hypersensitivity reactions from taxol

Journal of clinical oncology, 1990-07, Vol.8 (7), p.1263-1268

1990

Volltextzugriff (PDF)

Recommendations for the use of antiemetics : Evidence-based, clinical practice guidelines

Journal of clinical oncology, 1999-09, Vol.17 (9), p.2971-2994

1999

Volltextzugriff (PDF)

Comparison of instruments for measuring quality of life in patients with lung cancer

Seminars in oncology, 1996-04, Vol.23 (2 Suppl 5), p.31

1996

Volltextzugriff (PDF)

Normative data and trends in quality of life from the Lung Cancer Symptom Scale (LCSS)

Supportive care in cancer, 1999-05, Vol.7 (3), p.140-148

1999

Volltextzugriff (PDF)

Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1–Receptor Antagonist

The New England journal of medicine, 1999-01, Vol.340 (3), p.190-195

1999

Volltextzugriff (PDF)

Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer-A quantitative western blot analysis

Annals of neurology, 1990-05, Vol.27 (5), p.544-552

1990

Volltextzugriff (PDF)

Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the lung cancer symptom scale

Cancer, 1994-04, Vol.73 (8), p.2087-2098

1994

Volltextzugriff (PDF)

Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin

Journal of clinical oncology, 1994-10, Vol.12 (10), p.2204-2210

1994

Volltextzugriff (PDF)

Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response

Supportive care in cancer, 2006-04, Vol.14 (4), p.354-360

2006

Volltextzugriff (PDF)

Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials

Journal of clinical oncology, 1993-09, Vol.11 (9), p.1757-1762

1993

Volltextzugriff (PDF)

Guidelines for anti-emetic therapy: acute emesis

European journal of cancer (1990), 1999-03, Vol.35 (3), p.361-370

1999

Volltextzugriff (PDF)

Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin

Journal of clinical oncology, 1989-01, Vol.7 (1), p.108-114

1989

Volltextzugriff (PDF)

Multi-Institutional Phase I/II Trial of Oral Bexarotene in Combination With Cisplatin and Vinorelbine in Previously Untreated Patients With Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2001-05, Vol.19 (10), p.2626-2637

2001

Volltextzugriff (PDF)

Antiemetic therapy

Seminars in oncology, 1998-10, Vol.25 (5), p.577

Gralla, R J

1998

Volltextzugriff (PDF)

Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin

Journal of clinical oncology, 1994-05, Vol.12 (5), p.1045-1049

1994

Volltextzugriff (PDF)

1 – 25 von 467

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(416)
Mit Volltextzugriff
(383)

Publikationsform

Sprache

Englisch
(461)
Japanisch
(67)
Deutsch
(5)
Russisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(307)
Life Sciences & Biomedicine
(275)
Humans
(271)
Female
(175)
Male
(172)
Middle Aged
(158)
Oncology
(153)
Aged
(141)
Adult
(125)
Biological And Medical Sciences
(103)
Medical Sciences
(98)
Pharmacology. Drug Treatments
(75)
Neurosciences & Neurology
(74)
Lung Neoplasms - Drug Therapy
(72)
Clinical Neurology
(66)
Vomiting - Chemically Induced
(59)
Antineoplastic Agents - Adverse Effects
(58)
Drug Evaluation
(50)
Vomiting - Prevention & Control
(48)
Treatment Outcome
(47)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study

A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy

2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients

Request for regulatory guidance for cancer cachexia intervention trials

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference

Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy

Randomized Phase II Study of the Neurokinin 1 Receptor Antagonist CJ-11,974 in the Control of Cisplatin-Induced Emesis

2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting

Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy

A randomized trial of the electronic Lung Cancer Symptom Scale for quality-of-life assessment in patients with advanced non-small-cell lung cancer

Hypersensitivity reactions from taxol

Recommendations for the use of antiemetics : Evidence-based, clinical practice guidelines

Comparison of instruments for measuring quality of life in patients with lung cancer

Normative data and trends in quality of life from the Lung Cancer Symptom Scale (LCSS)

Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1–Receptor Antagonist

Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer-A quantitative western blot analysis

Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the lung cancer symptom scale

Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin

Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response

Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials

Guidelines for anti-emetic therapy: acute emesis

Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin

Multi-Institutional Phase I/II Trial of Oral Bexarotene in Combination With Cisplatin and Vinorelbine in Previously Untreated Patients With Advanced Non–Small-Cell Lung Cancer

Antiemetic therapy

Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin

Suchergebnisse filtern